* P3 Health Partners Inc PIII.OQ reported a quarterly
adjusted
loss of 22 cents per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-2.26. The mean expectation of five analysts
for the quarter was for a loss of 11 cents per share. Wall
Street expected results to range from -19 cents to -5 cents per
share.
* Revenue rose 34.3% to $346.86 million from a year ago;
analysts
expected $302.97 million.
* P3 Health Partners Inc's reported EPS for the quarter was
a loss
of 22 cents.
* The company reported a quarterly loss of $25.46 million.
* P3 Health Partners Inc shares had fallen by 27.7% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 12% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for P3 Health
Partners Inc is $4.25
This summary was machine generated from LSEG data March 28 at
09:41 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.11 -0.22 Missed
Sep. 30 2023 -0.22 -0.12 Beat
Jun. 30 2023 -0.13 -0.09 Beat
Mar. 31 2023 -0.67 -0.22 Beat